loader.my.id’s shares of the week

loader.my.id — Whilst the principle tale this week was once the Federal Reserve’s extra wary trail for charge cuts subsequent yr, there have been various person shares and sector tales that led to volatility for some large names. Listed below are loader.my.id’s shares of the week: Micron Generation (NASDAQ:), Novo Nordisk (NYSE:), MicroStrategy and Coinbase (NASDAQ:).

Micron Generation 

Micron Generation stocks tumbled greater than 16% Thursday after the corporate reported its newest quarterly income, with its outlook disappointing traders.

Whilst its Q1 EPS of $1.79 was once $0.06 higher than the analyst estimate of $1.73 and income for the quarter got here in at $8.71 billion, above the consensus estimate of $8.68 billion, Micron forecast quarterly income and benefit under Wall Side road estimates after the shut on Wednesday.

For Q2 2025, Micron sees its EPS between $1.33 and $1.53, under the consensus of $1.97. In the meantime, income for the quarter is anticipated to be between $7.7 billion and $8.1 billion, less than the consensus estimate of $8.97 billion.

Following the income free up, JPMorgan diminished its goal for the inventory to $145 from $180, telling traders that “in spite of the near-term weak point, we proceed to imagine the down-cycle in reminiscence will likely be short-lived.”

The financial institution expects marketplace prerequisites to enhance within the latter a part of 2025 as “modern DRAM provide stays tight and powerful AI server call for continues to pressure expansion in HBM/DDR5.”

Novo Nordisk

It was once a foul day on Friday for Novo Nordisk stocks with the inventory (on the time of writing) down 17.4% at the day.

The decline comes after the consequences from its segment 3 trial of CagriSema, its next-generation weight problems drug, dissatisfied traders.

The corporate’s REDEFINE 1 trial confirmed that individuals handled with CagriSema, a mixture of cagrilintide and semaglutide, accomplished a weight lack of 22.7% after 68 weeks.

On the other hand, whilst that was once statistically vital, it fell in need of the objective of 25%.

Following the scoop, rival Eli Lilly’s stocks jumped.

Reacting to the consequences, analysts at Wolfe Analysis mentioned: “Whilst we did not be expecting CagriSema to be a powerful competitor to Lilly’s Zepbound, we now see Lilly in a real magnificence of its personal with Zepbound, orforglipron and retatrutide.”

MicroStrategy, Coinbase

After mountaineering to over $108,000 previous within the week, the cost of fell from Wednesday onwards, touching a low of $92,118 on Friday.

Whilst MSTR and COIN are up on Friday, +8.1% and +1%, respectively, each names have declined for many of this week. MicroStrategy is down round 14% over the past 5 days, whilst Coinbase has declined over 11%.

Having a look at Bitcoin itself, whilst the associated fee plunged to begin with on Friday it has clawed again some floor. As of 13:58 ET, it’s buying and selling at $97,075.